Publication digest
The Publication Digests section of this Learning Zone provides simplified detail and graphical summaries of the latest published research on chronic kidney disease treatments.
The peer-reviewed article in this section describes clinical evidence for the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in the treatment of chronic kidney disease.
Dapagliflozin in patients with chronic kidney disease
The DAPA-CKD trial found that dapagliflozin is a safe and effective medication for the treatment of chronic kidney disease in patients with or without diabetes.
Canagliflozin in patients with type 2 diabetes and chronic kidney disease
The CREDENCE trial demonstrated canagliflozin was safe and effective for reducing the risk of adverse renal outcomes in patients with type 2 diabetes and chronic kidney disease.
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
The FIDELIO-DKD clinical trial explored ways to slow chronic kidney disease (CKD) progression and reduce cardiovascular morbidity and mortality in people with advanced CKD and type 2 diabetes.